CN113234644B - 一株可缓解etec致腹泻的格氏乳杆菌及其应用 - Google Patents
一株可缓解etec致腹泻的格氏乳杆菌及其应用 Download PDFInfo
- Publication number
- CN113234644B CN113234644B CN202110733250.6A CN202110733250A CN113234644B CN 113234644 B CN113234644 B CN 113234644B CN 202110733250 A CN202110733250 A CN 202110733250A CN 113234644 B CN113234644 B CN 113234644B
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- lactobacillus gasseri
- ccfm1182
- mice
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 88
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 68
- 230000000688 enterotoxigenic effect Effects 0.000 title claims abstract description 26
- 210000002966 serum Anatomy 0.000 claims abstract description 34
- 210000001630 jejunum Anatomy 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 108010067006 heat stable toxin (E coli) Proteins 0.000 claims abstract description 13
- 230000006378 damage Effects 0.000 claims abstract description 9
- 230000001575 pathological effect Effects 0.000 claims abstract description 7
- 230000000813 microbial effect Effects 0.000 claims description 8
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229940088592 immunologic factor Drugs 0.000 claims description 5
- 239000000367 immunologic factor Substances 0.000 claims description 5
- 230000002550 fecal effect Effects 0.000 claims description 4
- 235000021107 fermented food Nutrition 0.000 claims description 4
- 235000019985 fermented beverage Nutrition 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 235000011194 food seasoning agent Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 68
- 210000003608 fece Anatomy 0.000 abstract description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 24
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract description 18
- 235000019260 propionic acid Nutrition 0.000 abstract description 9
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 43
- 239000007788 liquid Substances 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 229960002181 saccharomyces boulardii Drugs 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000001580 bacterial effect Effects 0.000 description 24
- 239000001963 growth medium Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 238000009630 liquid culture Methods 0.000 description 15
- 238000012258 culturing Methods 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 238000000465 moulding Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000000741 diarrhetic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 102000004363 Aquaporin 3 Human genes 0.000 description 3
- 108090000991 Aquaporin 3 Proteins 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000012055 fruits and vegetables Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000235548 Blakeslea Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241001438367 Bredia Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000020244 animal milk Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020245 plant milk Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940126672 traditional medicines Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/45—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/24—Synthetic spices, flavouring agents or condiments prepared by fermentation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一株可缓解ETEC致腹泻的格氏乳杆菌及其应用,属于微生物技术领域。本发明筛选出了一株格氏乳杆菌CCFM1182,该菌株具有缓解腹泻的作用,具体体现在:显著降低腹泻小鼠的粪便含水量、显著缓解腹泻小鼠空肠的病理损伤、显著降低腹泻小鼠血清中的炎症因子水平、显著降低腹泻小鼠血清中肠毒素ST的含量、显著提高腹泻小鼠粪便中乙酸和丙酸的含量,在制备预防、治疗和/或辅助治疗腹泻的药品中,具有巨大的应用前景。
Description
技术领域
本发明涉及一株可缓解ETEC致腹泻的格氏乳杆菌及其应用,属于微生物技术领域。
背景技术
ETEC,肠毒性大肠埃希杆菌,定居于小肠表面,不损坏也不侵入肠黏膜上皮细胞,通过产生肠毒素引起分泌性腹泻,是人类霍乱样病人大便中新发现的一组致腹泻性大肠埃希杆菌,是发达国家“旅游者腹泻”的主要病原之一,是“成人霍乱综合征”的常见原因,也是小儿腹泻的重要病原,其发病率仅次于轮状病毒。
同时,ETEC也是引起家畜特别是幼畜(初生仔猪、犊牛等)腹泻的重要病原菌。初生仔猪感染ETEC后,常因剧烈水样腹泻和迅速脱水而死亡,发病率和死亡率均很高,给养猪业带来巨大负担。
ETEC会产生热不稳定毒素LT和热稳定性毒素ST,继而改变紧密连接的完整性,引发炎症、肠道功能异常,以及破坏离子、溶质和水的胞旁通道,最终导致腹泻。传统的氟喹诺酮类、利福昔明等抗生素对ETEC引起腹泻的预防是有效的,但通常只用于高危人群,如免疫功能严重抑制的患者。同时,这些传统药物也会产生很大的副作用,例如,常常会引发肠胃不适、中枢系统出现异常反应,以及头痛、头晕等症状。而且,长期服用这些传统药物会对肝造成损害。另外,长期服用这些传统药物还存在成本高、ETEC出现抗菌素耐药性等问题。上述缺陷均使得这些传统药物的使用受到限制,而替代方法的有效性还在研究中。
益生菌是通过定殖在人体内,改变宿主肠道菌群组成,进而代谢产生如短链脂肪酸等有益代谢物,以对宿主产生有益影响的一类菌。与普通的药物相比,益生菌具有安全性高、无副作用、不会出现耐药性和成本低等优势。并且,研究表明,少数益生菌确实可对一些特殊的疾病起到预防和/或治疗作用,虽然已有文献报道格氏乳杆菌缓解ETEC致腹泻的作用,但效果的优良性还不确定。
因此,发现一株可缓解ETEC致腹泻的益生菌或者优于已有报道的同种菌对预防和/或治疗腹泻这一疾病十分关键。
发明内容
本发明提供了一株格氏乳杆菌(Lactobacillus gasseri)CCFM1182,所述格氏乳杆菌(Lactobacillus gasseri)CCFM1182已于2021年04月16日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:61608,保藏地址为广州市先烈中路100号大院59号楼5楼。
本发明还提供了含有所述格氏乳杆菌CCFM1182的微生物制剂或发酵剂。
在一种实施方式中,所述微生物制剂中格氏乳杆菌CCFM1182的活菌数不低于1×1010CFU/mL或1×1010CFU/g。
在一种实施方式中,所述发酵剂还含有细胞保护剂。
本发明还提供了格氏乳杆菌CCFM1182在制备预防和/或治疗腹泻的药品中的应用。
在一种实施方式中,所述产品中,格氏乳杆菌CCFM1182的活菌数不低于1×1010CFU/mL或1×1010CFU/g。
在一种实施方式中,所述治疗腹泻包括如下至少一种作用:
(1)减少腹泻个体体重降低的危险性;
(2)降低腹泻个体的粪便含水量;
(3)缓解腹泻个体空肠的病理损伤;
(4)降低腹泻个体血清中的免疫因子水平;
(5)降低腹泻个体血清中的Toll样受体TLR4含量;
(6)降低腹泻个体血清中肠毒素ST的含量;
(7)提高腹泻个体粪便中短链脂肪酸的含量。
在一种实施方式中,所述腹泻个体是具有腹泻症状的哺乳动物。
在一种实施方式中,所述腹泻是由肠毒性大肠埃希杆菌诱发的。
本发明还提供一种药物,所述药品含有上述格氏乳杆菌CCFM1182、药物载体和/或药用辅料。
本发明还提供所述格氏乳杆菌CCFM1182或含格氏乳杆菌CCFM1182的微生物制剂在制备食品、饮品或调味品中的应用。
在一种实施方式中,所述食品包括但不限于含有所述格氏乳杆菌CCFM1182的保健食品;或由含有所述格氏乳杆菌CCFM1182的发酵剂生产得到的乳制品、豆制品、肉制品或果蔬制品。
在一种实施方式中,所述发酵剂的制备方法为:将所述格氏乳杆菌CCFM1182接种到培养基中,于37℃下培养18h,得到培养液;将培养液离心,得到菌体;将菌体用生理盐水重悬,得到发酵剂。
在一种实施方式中,所述培养基为MRS培养基。
本发明还提供了一种缓解腹泻症状的药品,所述药品含有上述格氏乳杆菌CCFM1182。
在一种实施方式中,所述产品中,上述格氏乳杆菌CCFM1182的活菌数不低于1×1010CFU/mL或1×1010CFU/g。
有益效果:
本发明筛选出了一株格氏乳杆菌(Lactobacillus gasseri)CCFM1182,此格氏乳杆菌(Lactobacillus gasseri)CCFM1182具有缓解腹泻的作用,具体体现在:
(1)显著提高腹泻小鼠的体重;
(2)显著降低腹泻小鼠的粪便含水量;
(3)显著缓解腹泻小鼠空肠的病理损伤;
(4)显著降低腹泻小鼠血清中的免疫因子水平;
(5)显著降低腹泻小鼠血清中肠毒素ST的含量;
(6)显著提高腹泻小鼠粪便中短链脂肪酸的含量;
因此,格氏乳杆菌(Lactobacillus gasseri)CCFM1182在制备预防和/或治疗腹泻的药品中,具有巨大的应用前景。
生物材料保藏
一株格氏乳杆菌(Lactobacillus gasseri)CCFM1182,分类学命名为Lactobacillus gasseri,已于2021年04月16日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:61608,保藏地址为广州市先烈中路100号大院59号楼5楼。
附图说明
图1:不同组小鼠的体重变化情况。
图2:不同组小鼠粪便含水量的变化情况。
图3:不同组小鼠空肠的病理损伤情况。
图4:不同组小鼠空肠绒毛的高度。
图5:不同组小鼠空肠隐窝的深度。
图6:不同组小鼠血清中IFN-γ的含量。
图7:不同组小鼠血清中TNF-α的含量。
图8:不同组小鼠血清中IL-6的含量。
图9:不同组小鼠血清中Toll样受体TLR4的含量。
图10:不同组小鼠血清中肠毒素ST的含量。
图11:不同组小鼠粪便中乙酸的含量。
图12:不同组小鼠粪便中丙酸的含量。
图1~12中:*:P<0.05,**:P<0.01,***:P<0.001。
具体实施方式
下面结合具体实施例和附图对本发明进行进一步的阐述。
下述实施例中涉及的BALB/c小鼠购自浙江维通利华公司;下述实施例中涉及的链霉素购自上海生工生物工程(上海)股份有限公司;下述实施例中涉及的产肠毒素大肠埃希氏菌(Escherichia coli ETEC O78:K80)购自中国工业微生物菌种保藏管理中心;下述实施例中涉及的布拉迪酵母CNCM I-745购自法国百科达有限公司;下述实施例中涉及的检测IFN-γ(货号:ML720140-2)、TNF-α(货号:ML720852-2)、IL-6(货号:ML720188-2)和IL-8(货号:ML063162-2)的ELISA试剂盒购自上海酶联生物科技有限公司;下述实施例中涉及的检测肠毒素ST(货号:ML701990-2)和水通道蛋白AQP3(货号:ML001869-2)的ELISA试剂盒购自上海酶联生物科技有限公司。
下述实施例中涉及的培养基如下:
MRS固体培养基:蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2HPO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、琼脂15g/L、半胱氨酸氨酸盐0.5g/L。
MRS液体培养基:蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2HPO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、半胱氨酸氨酸盐0.5g/L。
YPD固体培养基:酵母提取物10g/L、蛋白胨20g/L、葡萄糖20g/L、琼脂粉20g/L。
YPD液体培养基:酵母提取物10g/L、蛋白胨20g/L、葡萄糖20g/L。
实施例1:格氏乳杆菌CCFM1182的筛选及菌种鉴定
1、筛选:
以来源于甘肃永昌人粪便为样本,取0.5g保存于30%(v/v)甘油中的样本在无菌环境下加入装有4.5mL生理盐水的10mL离心管中,得到10-1稀释液,重复上述稀释步骤,依次得到10-2、10-3、10-4、10-5、10-6稀释液;分别吸取100μL不同梯度的梯度稀释液涂布于MRS固体培养基上,37℃培养72h,得到稀释涂布平板;挑取稀释涂布平板上的典型菌落分别接种至MRS液体培养基中,37℃培养48h,得到菌液。
2、鉴定:
将分离纯化的各菌液所对应的各菌株编号后,参照教科书《微生物学》(沈萍,陈向东主编)中所记载的步骤进行菌株鉴定、革兰氏染色、生理生化等实验,选取具有格氏乳杆菌典型特征的菌株,经实验获得两株菌,将两株菌分别命名为CCFM1182和QJSWX116L3(CCFM1182的生理生化特性见表1);其中,菌株鉴定过程如下:
提取CCFM1182和QJSWX116L3的基因组,将CCFM1182和QJSWX116L3的16S rDNA进行扩增和测序(由上海生工生物工程股份有限公司完成),将测序分析得到的16S rDNA序列分别在GenBank中进行比对,结果显示两株菌株均为格氏乳杆菌,但由于其16S rDNA序列不一致,分别为不同的菌株,故分别命名为格氏乳杆菌(Lactobacillus gasseri)CCFM1182和格氏乳杆菌(Lactobacillus gasseri)QJSWX116L3。
表1CCFM1182的生理生化特性
半乳糖 | + | 甘露糖 | + | 苦杏仁苷 | d | 蜜利比糖 | d |
纤维二糖 | + | 水杨素 | + | 乳糖 | d | 棉子糖 | d |
甘露醇 | - | 蔗糖 | + | 麦芽糖 | d | 海藻糖 | d |
注:+,超过90%的菌株为阳性;-大于或等于90%菌株为阳性;d,11%-89%的菌株为阳性;
3、菌液的制备:
挑取步骤1获得的格氏乳杆菌的单菌落接入MRS液体培养基中,于37℃厌氧培养24h,得到活化液;将活化液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃厌氧培养24h,得到一级种子液;将一级种子液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃厌氧培养24h,得到二级种子液;将二级种子液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃厌氧培养24h,得到菌液;将菌液6000g离心15min,收集沉淀;将沉淀用pH为7.4的PBS缓冲液洗涤两次后,6000g再次离心10min,得到菌体;用含有130g/L脱脂乳、20g/L海藻糖和20g/L蔗糖的保护剂溶液将格氏乳杆菌菌体重悬至细胞浓度为5×109CFU/mL,得到格氏乳杆菌菌液。
布拉迪酵母菌液的制备方法如下:
取一勺布拉迪酵母菌粉接入YPD液体培养基中,于28℃培养24h,得到活化液;将活化液按照1%(v/v)的接种量接入YPD液体培养基中,于28℃培养24h,得到一级种子液;将一级种子液按照1%(v/v)的接种量接入YPD液体培养基中,于28℃培养24h,得到二级种子液;将二级种子液按照1%(v/v)的接种量接入YPD液体培养基中,于28℃培养24h,得到菌液;将菌液6000g离心15min,收集沉淀;将沉淀用pH为7.4的PBS缓冲液洗涤两次后,6000g再次离心10min,得到菌体;用含有130g/L脱脂乳、20g/L海藻糖和20g/L蔗糖的保护剂溶液将布拉迪酵母菌体重悬至细胞浓度为5×109CFU/mL,得到布拉迪酵母菌菌液。
研究证明布拉迪酵母菌株没有病源性和扩散性(限定在消化道中,而不会向身体的任何其他位置扩散),通常生长良好,且具有独特生物活性,适合作为人和动物的益生菌使用。自分离出布拉迪酵母菌株以来,已进行了广泛的研究,共发表400多篇相关研究报告。1962年该菌株开始应用于治疗人类腹泻(作为处方药使用),1993开始用于改善单胃动物营养和健康的饲料添加剂,适用于母猪,仔猪,肉鸡,蛋鸡,犊牛,特种皮毛动物、水产动物等。布拉迪酵母已成为商业化菌株并且已有文献报道布拉迪酵母在缓解ETEC引起的腹泻的有益作用,因此,下述实施例中以布拉迪酵母作为阳性对照。
实施例2~7中,格氏乳杆菌(Lactobacillus gasseri)菌液和布拉迪酵母菌液均按本实施例的方法制备。
实施例2:格氏乳杆菌CCFM1182对腹泻小鼠体重和粪便含水量的影响
取BALB/c小鼠40只,于饲养室温为22~24℃,湿度为40%~60%,12h/12h昼夜交替,自由进食及饮水的条件下饲养1周后,随机分为5组,每组8只,5组分别为:对照组、造模组、灌胃布拉迪酵母菌液的布拉迪酵母组(CNCMI-745组)、灌胃格氏乳杆菌(Lactobacillusgasseri)QJSWX116L3菌液的QJSWX116L3组、灌胃格氏乳杆菌(Lactobacillus gasseri)CCFM1182菌液的CCFM1182组。
实验共3周:动物适应性饲养1周后开始实验。从造模前7天开始,一直持续到实验结束(不包括抗生素处理的那3天),对照组和造模组小鼠每只每天灌胃0.2mL按实施例1的方法制备的含有130g/L脱脂乳、20g/L海藻糖和20g/L蔗糖的保护剂溶液,布拉迪酵母组每只每天灌胃0.2mL按实施例1的方法制备的布拉迪酵母菌液,QJSWX116L3组每只每天灌胃0.2mL按实施例1的方法制备的格氏乳杆菌(Lactobacillus gasseri)QJSWX116L3菌液,CCFM1182组每只每天灌胃0.2mL按实施例1的方法制备的格氏乳杆菌(Lactobacillusgasseri)CCFM1182菌液;适应后的第2周为造模期,造模第1~3天,在小鼠饮用水中加入5g/L的链霉素,以消除BALB/c小鼠肠道正常菌群,造模第4~7天,用不含抗生素的无菌水代替含有链霉素的水作为小鼠饮用水,并且,对小鼠禁食18h,18h后,给每组小鼠每只灌胃0.2mL浓度为1.2×1011CFU/mL的ETEC O78:K80悬液(通过将ETEC O78:K80菌体溶于浓度为8.5g/L的生理盐水而得),连续灌胃4天,1天2次,每次间隔2h。
造模期间以及造模结束后,通过体重计测定每组小鼠体重;实验结束后,收集小鼠粪便,通过Lyobeta 5ps冻干机(西班牙泰事达公司)测定小鼠粪便的含水量,测定结果分别见图1~2。
由图1可知,在整个实验期间,造模组小鼠的体重变化和对照组并没有显著差异,药物组、布拉迪酵母组和格氏乳杆菌干预组均没有显著变化。
由图2可知,造模组小鼠粪便中的含水量是对照组小鼠的1.33倍(p<0.01),对照组的粪便含水量为46.73%,ETEC组的粪便含水量为61.98%。CCFM1182组小鼠粪便中的含水量为55.92%,与造模组小鼠相比,存在显著差异(p<0.05);在布拉迪酵母组也发现了与CCFM1182组相似的结果;而QJSWX116L3组小鼠粪便中的含水量为60.11%,与造模组小鼠相比,没有明显差异。
可见,格氏乳杆菌CCFM1182可有效缓解腹泻小鼠粪便含水量升高的症状,缓解效果和布拉迪酵母相当,而格氏乳杆菌QJSWX116L3则无此作用。
实施例3:格氏乳杆菌CCFM1182对腹泻小鼠空肠病理损伤情况的影响
动物模型的构建方法同实施例2,实验结束后,处死小鼠,取小鼠空肠,于4%(v/v)多聚甲醛中浸泡24h,得到固定好的空肠组织;将固定好的空肠组织依次进行脱水、透明、浸蜡后,用莱卡石蜡包埋机将组织包埋于蜡块中,得到包埋好空肠组织的蜡块;其中,脱水、透明、浸蜡的具体步骤如下:(1)脱水:将固定好的组织先依次经70%、80%和90%(v/v)梯度乙醇溶液进行脱水,每个梯度各30min,然后放入95%和100%(v/v)酒精溶液各2次,每次20min;(2)透明:将组织先放入酒精和二甲苯等体积比混合液中15min,然后放入二甲苯I和二甲苯II各15min;(3)浸蜡:将组织样放入62℃的石蜡I和石蜡II液体中各30min。
将包埋好空肠组织的蜡块用莱卡手动轮转切片机进行切片,切片厚度为5μm,得到空肠组织切片;将空肠组织切片经展片和捞片、烤片、苏木精染色、分化、漂洗、伊红复染、脱水、透明、封片,得到H&E空肠切片;其中,展片和捞片、烤片、苏木精染色、分化、漂洗、伊红复染、脱水、透明、封片的具体操作如下:(1)展片和捞片:将切片放于42℃恒温水浴中进行展片后用载玻片小心地捞出;(2)烤片:将切片放于60℃烘箱中过夜烤片;(3)苏木精染色:将切片先进行水化(即先将切片置于二甲苯I和二甲苯II各5min,然后依次放入100%、95%、90%、80%和70%(v/v)梯度酒精溶液中各5min,最后放入蒸馏水中3min),然后进行染色(即将切片放入苏木精染色液中约20s),最后进行水洗(即将切片用自来水冲洗约30min);(4)分化:将切片放入1%(v/v)盐酸乙醇溶液中7s,进行褪色;(5)漂洗:用自来水冲洗切片约20min;(6)复染:将切片浸入伊红染色液,立即取出;(7)脱水:将切片先依次放入95%(v/v)乙醇溶液I、95%(v/v)乙醇溶液II、70%(v/v)乙醇溶液,放入后立即取出,然后浸入80%(v/v)乙醇溶液50s,最后浸入100%(v/v)乙醇2min;(8)透明:将切片先浸入乙醇和二甲苯等体积比混合液1min,然后浸入二甲苯I和二甲苯II各2min;(9)封片:将切片用中性树胶封片。
用Pannoramic MIDI数字切片扫描仪扫描制作好的H&E空肠切片,并且,拍照观察小鼠空肠的绒毛长度和隐窝深度,观察结果见图3~5。
由图3~5可知,与对照组小鼠相比,造模组小鼠空肠的绒毛长度明显缩短了22.78%,隐窝深度明显增加了70.40%;与造模组小鼠相比,CCFM1182组小鼠空肠的绒毛长度增加了50.72%,隐窝深度降低了32.31%;QJSWX116L3组小鼠空肠的绒毛长度增加了31.36%,隐窝深度降低了8.34%;布拉迪酵母组小鼠空肠的绒毛长度增加了20.72%,隐窝深度降低了30.58%。
可见,格氏乳杆菌CCFM1182可有效缓解腹泻小鼠空肠的病理损伤情况,且在绒毛长度和隐窝深度降低方面的效果优于布拉迪酵母;而格氏乳杆菌QJSWX116L3的缓解效果相对较差。
实施例4:格氏乳杆菌CCFM1182对腹泻小鼠免疫因子水平的影响
动物模型的构建方法同实施例2,实验结束后,取血并处死小鼠,取小鼠血清,通过ELISA试剂盒测定每组小鼠血清中IFN-γ、TNF-α、IL-6、IL-8和TLR4的含量,检测结果见图6~9。
如图6所示,造模组小鼠血清中IFN-γ的含量为162.13pg/mL,比对照组(91.27pg/mL)显著升高;相比于造模组小鼠,CCFM1182组小鼠血清中IFN-γ的含量显著至88.85pg/mL(相对于造模组降低了45.20%),与对照组含量相当;QJSWX116L3组小鼠降低了1.63%;布拉迪酵母组小鼠降低了13.63%。
如图7所示,造模组小鼠血清中TNF-α的含量为236.13pg/mL,比对照组(157.42pg/mL)显著升高;相比于造模组小鼠,CCFM1182组小鼠血清中TNF-α的含量显著降低,降低了37.77%;QJSWX116L3组小鼠降低了7.86%%;布拉迪酵母组小鼠降低了14.53%。
如图8所示,造模组小鼠血清中IL-6的含量为14.38pg/mL,比对照组(7.94pg/mL)显著升高;相比于造模组小鼠,CCFM1182组小鼠血清中IL-6的含量显著降低,降低了42.90%;QJSWX116L3组小鼠降低了33.73%;布拉迪酵母组小鼠降低了24.24%。
如图9所示,造模组小鼠血清中TLR4的含量为5.23pg/mL,比对照组(3.30pg/mL)显著降低;相比于造模组小鼠,CCFM1182组小鼠血清中TLR4的含量显著降低,降低了48.72%;QJSWX116L3组小鼠降低了20.94%;布拉迪酵母组小鼠降低了19.99%。
可见,格氏乳杆菌CCFM1182可显著降低腹泻小鼠的免疫因子水平且效果优于布拉迪酵母;而格氏乳杆菌QJSWX116L3并无抗炎作用。
实施例5:格氏乳杆菌CCFM1182对腹泻小鼠血清中肠毒素ST含量的影响
动物模型的构建方法同实施例2,实验结束后,取血并处死小鼠,取小鼠血清,通过ELISA试剂盒测定每组小鼠血清中肠毒素ST和水通道蛋白AQP3的含量,检测结果见图10。
如图10所示,造模组小鼠血清中肠毒素ST的含量为970.41pg/mL,比对照组显著升高;相比于造模组小鼠,CCFM1182组小鼠血清中肠毒素ST的含量显著降低了33.72%,接近于对照组的623.44pg/mL;QJSWX116L3组小鼠血清中肠毒素ST的含量降低了14.32%;布拉迪酵母组小鼠血清中肠毒素ST的含量降低了28.99%。
可见,格氏乳杆菌CCFM1182可显著降低腹泻小鼠血清中肠毒素ST的含量,且效果优于布拉迪酵母,而格氏乳杆菌QJSWX116L3并不明显;格氏乳杆菌CCFM1182提高腹泻小鼠血清中水通道蛋白AQP3的效果没有QJSWX116L3和布拉迪酵母的好。
实施例6:格氏乳杆菌CCFM1182对腹泻小鼠粪便中短链脂肪酸含量的影响
动物模型的构建方法同实施例2,实验结束后,收集小鼠粪便置于液氮中,后转移至-80℃冰箱,在进行短链脂肪酸含量的检测前取出,进行真空冷冻干燥,准确称取0.05g冻干后的粪便样品溶解于0.5mL饱和氯化钠溶液中,浸泡30min,组织匀浆机匀浆,加入0.02mL浓度为10%的硫酸,震荡30s,在通风橱内向粪便溶液中准确加入1mL乙醚溶液,震荡30s后离心15min(8000g、4℃),移取上清液至含有0.25g无水硫酸钠的离心管中,震荡均匀,离心15min(8000g、4℃),取上清至气质容量瓶中,通过GCMS检测短链脂肪酸含量,检测结果见图11~12。
如图11~12所示,造模组小鼠粪便中乙酸、丙酸的含量和对照组几乎无明显差别;CCFM1182组小鼠粪便中乙酸、丙酸的含量与造模组相比显著上调,分别是造模组的2.04倍和2.18倍;QJSWX116L3组小鼠粪便中乙酸、丙酸的含量分别是造模组的2.58倍和1.78倍,;布拉迪酵母组小鼠粪便中乙酸、丙酸的含量分别是造模组的1.26倍和0.84倍。此外,CCFM1182组的乙酸含量比布拉迪酵母组增加了61.36%,其丙酸水平是布拉迪酵母组的2.60倍。
可见,格氏乳杆菌CCFM1182可显著提高腹泻小鼠粪便中乙酸和丙酸的含量,且效果优于布拉迪酵母,其中对丙酸的调节优于格氏乳杆菌QJSWX116L3。
实施例7:格氏乳杆菌CCFM1182用于制备药物
格氏乳杆菌CCFM1182可用于制备片剂,片剂的具体制备过程如下:
挑取实施例1获得的格氏乳杆菌(Lactobacillus gasseri)CCFM1182的单菌落接入MRS液体培养基中,于37℃培养16h,得到菌浓数量级达1×107CFU/mL的活化液;将活化液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃培养16h,得到一级种子液;将一级种子液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃培养16h,得到二级种子液;将二级种子液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃培养16h,得到菌液;将菌液6000g离心15min,收集沉淀;将沉淀用pH为7.4的PBS缓冲液洗涤两次后,6000g再次离心10min,得到菌体;用含有130g/L脱脂乳、20g/L海藻糖和20g/L蔗糖的保护剂溶液将格氏乳杆菌菌体重悬至细胞浓度为1×1010CFU/mL,得到格氏乳杆菌菌液;将格氏乳杆菌菌液冷冻干燥,得到格氏乳杆菌菌粉;在格氏乳杆菌菌粉中加入占格氏乳杆菌菌菌粉总重计2%的硬脂酸作润滑剂、3%的羧甲基纤维素钠(CMC-Na)作粘合剂后进行压片,得到片剂。
取上述方法制备的片剂以1g/只的剂量每天灌胃ETEC致腹泻小鼠,连续两周,可有效缓解小鼠腹泻的症状,在预防和/或治疗腹泻上有极好的效果。
实施例8:格氏乳杆菌CCFM1182用于制备菌粉
格氏乳杆菌CCFM1182可用于制备菌粉,菌粉的具体制备过程如下:
挑取实施例1获得的格氏乳杆菌(Lactobacillus gasseri)CCFM1182的单菌落接入MRS液体培养基中,于37℃培养16h,得到菌浓数量级达1×107CFU/mL的活化液;将活化液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃培养16h,得到一级种子液;将一级种子液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃培养16h,得到二级种子液;将二级种子液按照1%(v/v)的接种量接入MRS液体培养基中,于37℃培养16h,得到菌液;将菌液6000g离心15min,收集沉淀;将沉淀用pH为7.4的PBS缓冲液洗涤两次后,6000g再次离心10min,得到菌体;用含有130g/L脱脂乳、20g/L海藻糖和20g/L蔗糖的保护剂溶液将格氏乳杆菌菌体重悬至细胞浓度为1×1010CFU/mL,得到格氏乳杆菌菌液;将格氏乳杆菌菌液冷冻干燥,得到菌粉。
可选地,还可将其它类型的益生菌与约氏乳杆菌混合,制备复配菌粉。
取上述方法制备菌粉以1g/只的剂量每天灌胃ETEC致腹泻小鼠,连续两周,可有效缓解小鼠腹泻的症状,在预防和/或治疗腹泻上有极好的效果。
实施例9:格氏乳杆菌CCFM1182用于制备发酵食品
以将格氏乳杆菌CCFM1182或实施例8制备的含格氏乳杆菌CCFM1182的菌粉用于制备发酵食品或发酵饮品。
用于制备发酵饮品的原料可选自:动物乳、植物乳、果蔬汁、谷物汁中的一种或多种的混合。
用于制备发酵食品的原料可选自:动物乳、植物乳、果蔬原料,谷物粉或谷物混合物,肉制品原料。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (8)
1.一株格氏乳杆菌(Lactobacillus gasseri)CCFM1182,其特征在于,所述格氏乳杆菌(Lactobacillus gasseri)已于2021年04月16日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:61608。
2.含有权利要求1所述格氏乳杆菌CCFM1182的微生物制剂。
3.根据权利要求2所述的微生物制剂,其特征在于,所述微生物制剂中格氏乳杆菌CCFM1182的活菌数不低于1×1010 CFU/mL或1×1010 CFU/g。
4.权利要求1所述的格氏乳杆菌CCFM1182在制备预防和/或治疗腹泻的药物中的应用。
5.根据权利要求4所述的应用,其特征在于,所述治疗腹泻包括如下至少一种作用:
(1)减少腹泻个体体重降低的危险性;
(2)降低腹泻个体的粪便含水量;
(3)缓解腹泻个体空肠的病理损伤;
(4)降低腹泻个体血清中的免疫因子水平;
(5)降低腹泻个体血清中的Toll样受体TLR4含量;
(6)降低腹泻个体血清中肠毒素ST的含量;
(7)提高腹泻个体粪便中短链脂肪酸的含量;
所述腹泻个体是具有腹泻症状的哺乳动物;
所述腹泻是由肠毒性大肠埃希杆菌诱发的。
6.含权利要求1所述格氏乳杆菌CCFM1182的药物,其特征在于,还含有药物载体和/或药用辅料。
7.根据权利要求6所述的药物,其特征在于,格氏乳杆菌CCFM1182的活菌数不低于1×1010 CFU/mL或1×1010 CFU/g。
8.权利要求1所述的格氏乳杆菌CCFM1182或权利要求2~3任一所述的微生物制剂在制备发酵食品、饮品或调味品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110733250.6A CN113234644B (zh) | 2021-06-30 | 2021-06-30 | 一株可缓解etec致腹泻的格氏乳杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110733250.6A CN113234644B (zh) | 2021-06-30 | 2021-06-30 | 一株可缓解etec致腹泻的格氏乳杆菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113234644A CN113234644A (zh) | 2021-08-10 |
CN113234644B true CN113234644B (zh) | 2022-08-23 |
Family
ID=77141228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110733250.6A Active CN113234644B (zh) | 2021-06-30 | 2021-06-30 | 一株可缓解etec致腹泻的格氏乳杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113234644B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112458027B (zh) * | 2020-12-16 | 2022-08-02 | 江南大学 | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 |
CN117402794B (zh) * | 2023-12-12 | 2024-02-27 | 四川厌氧生物科技有限责任公司 | 一种加氏乳杆菌及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4853986B2 (ja) * | 2001-09-20 | 2012-01-11 | 雪印メグミルク株式会社 | 炎症性腸疾患及び過敏性腸症候群の予防・治療剤 |
WO2014077365A1 (ja) * | 2012-11-16 | 2014-05-22 | カルピス株式会社 | 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 |
RU2641258C1 (ru) * | 2016-11-08 | 2018-01-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Пробиотический штамм Lactobacillus gasseri и его композиция с лактоферрином для профилактики диареи, некротизирующего энтероколита и сепсиса, вызываемых штаммами Escherichia coli у преждевременно рожденных детей |
MX2020012594A (es) * | 2018-05-23 | 2021-04-28 | Ko Biolabs Inc | Cepa de lactobacillus gasseri kbl697 y uso de la misma. |
CN112239739B (zh) * | 2020-10-30 | 2022-06-10 | 江南大学 | 一株可缓解etec致腹泻的植物乳杆菌及其应用 |
-
2021
- 2021-06-30 CN CN202110733250.6A patent/CN113234644B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113234644A (zh) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112694992B (zh) | 一株可缓解腹泻的两歧双歧杆菌及其应用 | |
CN113234644B (zh) | 一株可缓解etec致腹泻的格氏乳杆菌及其应用 | |
CN113088463B (zh) | 一种具有益生特性的嗜酸乳杆菌及其应用 | |
CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
CN113005049B (zh) | 一株可缓解腹泻的短双歧杆菌及其应用 | |
CN110495522B (zh) | 一种饲料用中药微生态制剂 | |
CN114540242A (zh) | 一种能够预防和/或治疗腹泻的动物双歧杆菌及其应用 | |
CN106967645B (zh) | 一株高产单宁酶的嗜酸乳杆菌及其在防治仔猪腹泻中的应用 | |
CN110893194A (zh) | 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用 | |
CN112239739B (zh) | 一株可缓解etec致腹泻的植物乳杆菌及其应用 | |
CN114231470A (zh) | 一株可缓解溃疡性结肠炎的嗜酸乳杆菌及其应用 | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN114540239B (zh) | 一株兔源性预防宠物腹泻屎肠球菌zjuids-r1及其应用 | |
CN116200305A (zh) | 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 | |
CN113234643B (zh) | 一株可缓解etec致腹泻的约氏乳杆菌及其应用 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
CN112538441B (zh) | 缓解etec所致腹泻的罗伊氏乳杆菌ccfm1144及应用 | |
CN110591986B (zh) | 一株可缓解类风湿性关节炎的干酪乳杆菌及其应用 | |
CN117264814A (zh) | 一种对消化道疾病具有预防治疗效果的鼠李糖乳酪杆菌 | |
CN114908009B (zh) | 一株口粘液乳杆菌pr63及其应用 | |
CN116836852A (zh) | 缓解溃疡性结肠炎的罗伊氏乳杆菌zjuids09及其应用 | |
CN107586746B (zh) | 一株具有防治奶牛乳房炎功效的乳酸菌及其应用 | |
CN112779196B (zh) | 一种用于降低母猪便秘发病率的复合益生菌制剂及其制备方法和应用 | |
CN110982737A (zh) | 一种犬用生物被膜态乳酸菌剂及其制备方法 | |
CN116790402B (zh) | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |